Tenax Therapeutics (TENX) EBIAT (2016)
Historic EBIAT for Tenax Therapeutics (TENX) over the last 6 years, with Q4 2016 value amounting to -$33.9 million.
- Tenax Therapeutics' EBIAT fell 17972.22% to -$33.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$54.9 million, marking a year-over-year increase of 6433.49%. This contributed to the annual value of -$17.6 million for FY2024, which is 12827.13% down from last year.
- According to the latest figures from Q4 2016, Tenax Therapeutics' EBIAT is -$33.9 million, which was down 17972.22% from -$4.3 million recorded in Q3 2016.
- Tenax Therapeutics' 5-year EBIAT high stood at $107.6 million for Q2 2012, and its period low was -$117.0 million during Q2 2013.
- Moreover, its 4-year median value for EBIAT was -$4.6 million (2016), whereas its average is -$9.2 million.
- Within the past 5 years, the most significant YoY rise in Tenax Therapeutics' EBIAT was 367659.93% (2012), while the steepest drop was 38687.41% (2012).
- Quarter analysis of 4 years shows Tenax Therapeutics' EBIAT stood at -$1.6 million in 2012, then tumbled by 7415.94% to -$117.0 million in 2013, then skyrocketed by 89.66% to -$12.1 million in 2015, then plummeted by 179.72% to -$33.9 million in 2016.
- Its EBIAT stands at -$33.9 million for Q4 2016, versus -$4.3 million for Q3 2016 and -$4.6 million for Q2 2016.